Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Hematology
•
Nephrology
•
Glomerulonephritis
Would you consider initiating eculizumab without plasmapheresis as initial therapy for a patient with renal TMA who has a low suspicion of TTP based on a scoring algorithm?
Frimat M, et al., PMID 39342982
Related Questions
In patients with lupus nephritis, and MAHA with positive anti-phospholipid autoantibodies, what are the considerations to use or not use anti-coagulation therapy?
How would you approach post-operative VTE prophylaxis for renal transplant in patients with a prior history of provoked VTE?
How would you approach the treatment for patients with renal-limited ANCA vasculitis who have persistent proteinuria, hematuria, and ANCA titers and have completed a steroid taper and received three doses of rituximab?
How do you monitor multiple myeloma in patients receiving dialysis?
What are your management strategies for patients with biopsy proven IgA nephropathy with rapidly progressive glomerulonephritis?
How does your approach to the differential diagnosis of membranous nephropathy change when PLA2R positivity is detected alongside a chronic viral infection such as HIV, HBV, or HCV?
How do you address patient concerns regarding the necessity of REMS monitoring when prescribing sparsentan?
What do you feel are the potential barriers to widespread use of obinutuzumab in proliferative lupus nephritis?
Do you routinely check serum phosphorus levels after IV iron therapy?
How do various therapeutic approaches for IgA nephropathy target the different stages of the four-hit hypothesis?
